Adicet Bio Advances Phase 1 Trial for Autoimmune Treatment, Analysts Predict 634.93% Upside
ByAinvest
Thursday, Jul 24, 2025 9:41 am ET1min read
ACET--
ADI-001, an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting B-cells via an anti-CD20 CAR, is being evaluated for the treatment of various autoimmune diseases. The Phase 1 trial is enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE), SSc, IIM, SPS, and AAV. The trial has four separate arms, with each arm focusing on a specific autoimmune disease [1].
Analysts have responded positively to this development. They forecast an average target price of $6.00, with an upside of 634.93% from the current price of $0.82. The consensus recommendation from seven brokerage firms is 1.9, indicating an "Outperform" status [2].
Julie Maltzman, M.D., Chief Medical Officer of Adicet Bio, expressed optimism about the trial's progress and the potential of ADI-001 to offer transformative benefits for several autoimmune diseases, including SSc. Preliminary clinical data from the trial is expected in the second half of 2025 [1].
Adicet Bio is a clinical stage biotechnology company focusing on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company aims to advance a pipeline of "off-the-shelf" gamma delta T cells engineered with CARs to facilitate durable activity in patients [1].
References:
[1] https://www.morningstar.com/news/business-wire/20250724025385/adicet-bio-announces-first-systemic-sclerosis-ssc-patient-dosed-in-ongoing-phase-1-clinical-trial-of-adi-001-in-autoimmune-diseases
[2] https://investingnews.com/adicet-bio-announces-first-systemic-sclerosis-patient-dosed-in-ongoing-phase-1-clinical-trial-of-adi-001-in-autoimmune-diseases/
MORN--
Adicet Bio has progressed in its Phase 1 trial for autoimmune treatment, administering the initial dose to a patient with systemic sclerosis. Analysts forecast an average target price of $6.00, with an upside of 634.93% from the current price of $0.82. The consensus recommendation from 7 brokerage firms is 1.9, indicating an "Outperform" status.
Adicet Bio, Inc. (Nasdaq: ACET) has made significant progress in its Phase 1 clinical trial for autoimmune treatments, marking a key milestone with the first systemic sclerosis (SSc) patient dosed in the ongoing study of ADI-001. The company announced this development on July 24, 2025 [1].ADI-001, an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting B-cells via an anti-CD20 CAR, is being evaluated for the treatment of various autoimmune diseases. The Phase 1 trial is enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE), SSc, IIM, SPS, and AAV. The trial has four separate arms, with each arm focusing on a specific autoimmune disease [1].
Analysts have responded positively to this development. They forecast an average target price of $6.00, with an upside of 634.93% from the current price of $0.82. The consensus recommendation from seven brokerage firms is 1.9, indicating an "Outperform" status [2].
Julie Maltzman, M.D., Chief Medical Officer of Adicet Bio, expressed optimism about the trial's progress and the potential of ADI-001 to offer transformative benefits for several autoimmune diseases, including SSc. Preliminary clinical data from the trial is expected in the second half of 2025 [1].
Adicet Bio is a clinical stage biotechnology company focusing on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company aims to advance a pipeline of "off-the-shelf" gamma delta T cells engineered with CARs to facilitate durable activity in patients [1].
References:
[1] https://www.morningstar.com/news/business-wire/20250724025385/adicet-bio-announces-first-systemic-sclerosis-ssc-patient-dosed-in-ongoing-phase-1-clinical-trial-of-adi-001-in-autoimmune-diseases
[2] https://investingnews.com/adicet-bio-announces-first-systemic-sclerosis-patient-dosed-in-ongoing-phase-1-clinical-trial-of-adi-001-in-autoimmune-diseases/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet